Analytical Method Development and Validation for Estimation of Ranitidine in Solid Dosage Form by UV-Spectrophotometric Method

SUBRATA PAUL¹, LABANI BARAI², MD. FARUK HUSEN³, SABARNI SARKER⁴, TARUN KUMAR PAL⁵, PUJA BAL⁶, MD. ABDUL MATIN SARKER⁷, SYEDA SAIMA ALAM⁸ and SHETA BISWAS⁹*

¹Department of Pharmacy, University of Rajshahi, Rajshahi-6205, Bangladesh.
²Department of Pharmacy, University of Asia Pacific, Dhaka-1205, Bangladesh.
³Department of Applied Chemistry and Chemical Engineering, University of Rajshahi, Rajshahi-6205, Bangladesh.
⁴Department of Pharmacy, Faculty of Life and Earth Sciences, Jagannath University, Dhaka-1100, Bangladesh.
⁵Department of Chemistry, Rajshahi University of Engineering & Technology, Rajshahi-6204, Bangladesh.
⁶Department of Pharmacy, Faculty of Allied Health Science, Daffodil International University, Dhaka-1207, Bangladesh.
⁷Department of Pharmacy, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh.
⁸Department of Food Technology and Nutrition Science, Noakhali Science and Technology University, Noakhali-3814, Bangladesh.
⁹Department of Biochemistry and Molecular Biology, Noakhali Science and Technology University, Noakhali-3814, Bangladesh.

*Corresponding author E-mail: shwetabio1992@gmail.com
http://dx.doi.org/10.13005/ojc/360621

(Received: October 28, 2020; Accepted: December 15, 2020)

ABSTRACT

Ranitidine is a histamine-2 receptor blocker and it is effective against peptic ulcer, gastroesophageal reflux disease and heart burn. The main objective of this study was to develop and validate an easy, affordable and cost-effective method for the determination of ranitidine in tablet dosage form. The development and validation study was performed under the guidance of ICH and USP. Results showed that the proposed validated method has good accuracy with % RSD of 0.60. Repeatability and intermediate precision suggested good precision whereas the value of correlation coefficient 0.9999 confirmed about the linearity of the method. The system suitability data and similarity factors were also found within the permissible range. The specificity study revealed that there was no placebo and diluent effect on the absorbance. Further, stability study of analytical solutions as well as estimation of drug content from market products were also performed.

Keywords: Ranitidine, Method Validation, UV-Spectrophotometer, Accuracy, Linearity.
INTRODUCTION

Ranitidine or (Z)-N-[2-[[5-[(dimethylamino)methyl][furan-2-yl]methyl]sulfanyl]ethyl]-N'-methyl-2-nitroethene-1,1-diamine (Fig. 1) was one of the earliest H₂ histamine receptors antagonist approved for clinical use¹. Soon after its discovery ranitidine was indicated against a variety of pathologies associated to gastric hyper-secretory conditions, for example, gastric ulcer, reflux acidity and heartburn²,³,⁴. In the late 1970’s the water solubility of ranitidine had been improved with its salt form ranitidine hydrochloride and soon it became the world’s best-selling drug⁵. It was among the top-selling pharmaceutical products before Food and Drugs Administration (FDA) found a carcinogenic impurity named N-nitrosodimethylamine (NDMA) above limit in some of the products in 2019 and subsequently recalled it from the market⁶,⁷. However, FDA is still investigating on the impurity issue and once this issue is resolved, the production may or may not resume⁷.

Analytical method validation techniques can check the repeatability of analytical methods. The current study was designed to establish and validate a routine analytical method regarding potency and stability of ranitidine hydrochloride using UV-Visible spectrophotometry. Water was chosen as the diluent as it is suitable and cost-effective for the analysis of the drug⁸. The method was validated according to ICH and USP guidelines²²,²³.

MATERIALS AND METHODS

Instrumentation and reagents

UV-Visible spectrophotometer (3600 plus, Shimadzu, Japan) was used for the development and validation of the method. Sartorius analytical balance was used to measure the weight of standard and sample. Centrifugation of solution was performed by using Centrifuge EBA-20 (Sandberg). Ranitidine hydrochloride tablet and ranitidine hydrochloride USP reference standard were used for this experiment. Purified water was prepared in the laboratory.

Preparation of standard 1 and standard 2

20.10 mg Ranitidine hydrochloride RS (equivalent to 18 mg of Ranitidine) was transferred into a 50 mL amber volumetric flask. Water was used as a diluent to obtain the volume about 30 mL. Afterward, the solution was sonicated for 15 min and cooled down. Again, diluent (water) was applied to make the volume up to mark. Further, 1 mL of this solution was withdrawn to another 50 mL volumetric flask. The resulting solution has a concentration of 0.072 mg/mL. For the preparation of standard 2, the process was repeated.

Sample preparation

20 tablets were weighed and crushed to make fine powder. Powder equivalent to 150 mg of ranitidine was poured into a 100 mL amber volumetric flask. After adding 70 mL diluent it was sonicated for 15 minutes. Then, the solution was cooled down and it was made up to the mark by adding diluent. The centrifugation of the solution at 3000 rpm for 10 min was carried out. Further, 1 mL was transferred into 50 mL amber volumetric flask.
Validation parameters

The parameters considered for the experiment include accuracy, precision, linearity, specificity, robustness and system suitability.

Accuracy

Accuracy was ascertained by applying of recovery studies. It was done by adding a known amount of standard above and below the label claim of pellets i.e. 80%, 100% & 120%\textsuperscript{24}. Each level was carried out in triple times.

Preparation of sample for 80%, 100% and 120% recovery

Accurately weighed 133.6 mg of ranitidine hydrochloride (equivalent to 120 mg of ranitidine) and 177.4 mg of placebo for 80%, 167 mg of ranitidine hydrochloride (equivalent to 150 mg of ranitidine) and 144 mg of placebo for 100% and 200.94 mg of ranitidine hydrochloride (equivalent to 180 mg of ranitidine) and 110.06 mg of placebo for 120% into a 100 mL volumetric flask. After that, about 70 mL diluent was added and sonicated for 15 minutes. Then the solution was cooled down and diluent was added for making the volume up to the mark. Furthermore, centrifugation was performed at 3000 rpm for 20 minutes. Then, 1 mL of the solution was transferred into a 50 mL amber volumetric flask and same solvent was added to make the volume up to the mark. Again, 6 mL of the solution was taken into 25 mL amber volumetric flask and it was filled up to mark by adding water. The percent of recovery was calculated using the following equation.

Linearity

The method is valid for its desired use throughout the specified ranges which can be assured from the linearity of a test result. Incremental concentrations of samples were prepared in the working range.

Preparation of linearity sample

Linearity samples were prepared at concentrations 50%, 80%, 100%, 120% and 150% of the theoretical claim of a single unit\textsuperscript{26}. Accurately weighed 37.5 mg ranitidine was transferred into a 25 mL amber volumetric flask and diluent was added to fill the volume. Then 1 mL of this solution was diluted to make 50 mL with water. This is the mother stock solution with the concentration of 0.03 mg/mL.

For 50% sample, 6 mL of the mother solution was taken into a 50 mL volumetric flask and diluent was added up to the mark. The final concentration will be 0.0036 mg/mL. Again for 80%, 100%, 120% and 150% sample, 5 mL, 6 mL, 7 mL, 9 mL of the mother solution were taken into a 25 mL volumetric flask and required amount of diluent was added to
make the volume up to mark. The concentration became 0.006 mg/mL, 0.0072 mg/mL, 0.0084 mg/mL, 0.0108 mg/mL, respectively. The absorbance’s of samples were taken as per the assay method and a graph was plotted of concentration of ranitidine versus the corresponding absorbance.

**Robustness**
Robustness of the developed method was evaluated by the capability of a method to produce similar result upon tiny thoughtful change of different parameters of the experimental method\(^27\). The experiment was carried out in three different wavelengths (312 nm, 314 nm and 316 nm), performed with amber and colorless glassware, with and without centrifuge as well as filtration.

**Specificity**
The specificity can be defined as the capacity of an analytical method to estimate exactly a particular analyte in the presence of excipient or other impurities\(^28\). For the preparation of the placebo sample, accurately weighed and transferred 144 mg of placebo into a 100 mL volumetric flask. Then followed the sample and standard preparation steps which was mentioned earlier. The spectrum of placebo, sample and standard solutions were taken separately for evaluating the specificity of proposed method.

**System suitability study**
The system suitability of a method refers to the suitability of a method for analysis and an integral part of method development. It refers to the checking of system to ensure the performance of that system. In this study, absorbance of five replicates of standard were taken to assess the system suitability of the method. It was executed before initiating the analysis\(^29\).

**Stability of analytical solutions**
Stability of analytical solutions (standard solution and sample solution) were determined by analyzing the solutions at 0 h and at 72 h in room temperature (30°C).

**RESULTS AND DISCUSSION**

**Accuracy**
Accuracy of the analytical method was evaluated by estimation of percentage recovery of known amount of standard. The attained percentage of recovery were within the range of 99.22–100.94% with %RSD of 0.60, which supports the compatibility of the method for routine drug analysis (Table 1).

| Amount Recovered (mg) | %Recovery (Y/X*100) | Mean | %RSD |
|-----------------------|---------------------|------|------|
| 100.01                | 99.97               | 0.73 |
| 100.68                | 99.22               |      |
| 100.13                | 99.81               | 0.68 |
| 100.60                | 100.23              | 0.37 |

Acceptance limit: Mean (%recovery) 98.00 %-102.00% and %RSD must be ≤ 2.00%

**Precision**
A method is precise when under specified conditions, different measurements from the similar sample shows results in a specific and close range.\(^30\) In this experiment, intra-assay precision (repeatability) and intermediate precision were executed. Intermediate precision was performed by two different analysts on a different day, different instrument and it was found that the difference between the two results was 0.10 %(acceptance Limit: ± 2.00%). On the other hand, %RSD for repeatability and intermediate precision were 1.07% and 0.68%, respectively which is well below the permissible range, ≤ 2.00% (Table 2 & 3).
Table 2: Repeatability study for Ranitidine

| Determination No | Weight of Sample (mg) | Weight of Std. (mg) | Result(mg/Unit Dose) | Assay(%) |
|------------------|-----------------------|--------------------|----------------------|---------|
| 1                | 323.4                 |                    | 154.45               | 102.97  |
| 2                | 323.7                 |                    | 154.44               | 102.96  |
| 3                | 319.9                 |                    | 156.01               | 104.01  |
| 4                | 321.9                 | 20.42              | 155.27               | 103.52  |
| 5                | 328.7                 |                    | 152.11               | 101.41  |
| 6                | 328.9                 |                    | 151.98               | 101.32  |
| Mean of % Assay  |                      |                    | 102.69               | %RSD    |
|                  |                       |                    | %RSD 1.07            |         |

Acceptance Limit: %RSD must be ≤ 2.00%

Table 3: Intermediate precision study for Ranitidine

| Analyst 1 (Day 1) | Analyst 2 (Day 2) |
|-------------------|-------------------|
| Determination No. | Weight of sample (mg) | Assay (%) | Determination No. | Weight of sample (mg) | Assay (%) |
| 1                 | 323.4              | 102.97    | 1.               | 329.7              | 102.15   |
| 2                 | 323.7              | 102.96    | 2.               | 328.7              | 102.41   |
| 3                 | 319.9              | 104.01    | 3.               | 323.9              | 103.98   |
| 4                 | 321.9              | 103.52    | 4.               | 328.9              | 102.27   |
| 5                 | 328.7              | 101.41    | 5.               | 327.7              | 102.63   |
| 6                 | 328.9              | 101.32    | 6.               | 329.5              | 102.11   |
| Mean              | 102.69             | 102.59    | %RSD             | 1.07              | 0.68     |

Difference between two results: 0.10 %, Acceptance Limit: ± 2.00% difference between two results and %RSD must be ≤ 2.00%

**Linearity**

If concentration measurements over a different set of independent variables, such as absorbance, result in a proportional relationship, the method is said to be linear. The linearity of ranitidine was estimated in the concentration range of 0.0036 mg/mL to 0.0108 mg/mL. The line must be linear within the studied concentration range and the correlation coefficient of 0.9999 is generally regarded as acceptable. Regression analysis deduced a linear equation: \( y = 46.295x - 0.0014 \) \( r^2 = 0.9999 \), indicating a linear relationship between the concentration of analyte and absorbance (Figure 2).

Table 4: Linearity study for Ranitidine

| Determination No | Concentration (mg/ml)(X Axis) | Absorbance (Y Axis) |
|------------------|-------------------------------|---------------------|
| 1                | 0.0036                        | 0.16302             |
| 2                | 0.0059                        | 0.26962             |
| 3                | 0.0071                        | 0.32835             |
| 4                | 0.0083                        | 0.38574             |
| 5                | 0.0108                        | 0.49754             |

Correlation of coefficient \( r^2 = 0.9999 \); Acceptance Limit: The value of \( r^2 \) must be > 0.999

**Robustness**

Robustness study showed that a minor change of method parameters doesn’t influence much on the final results (Table 5). Small changes in parameter did not affect much on the percentage of drug content and in every case the percentage RSD was found within the permissible range which support robustness of the proposed method.

**Specificity**

The specificity of the method was evaluated by comparing the absorbance of diluent plus placebo solution, standard solution, and sample solution. Fig. 3 demonstrated that there was no effect of diluent and placebo solution.
Table 5: Robustness study

| Parameters          | % Drug Content | % Target | % RSD |
|---------------------|----------------|----------|-------|
| Filtration: Yes     | 97.06          | 100      | 1.49  |
| Filtration: No      | 99.14          | 100      |       |
| Centrifuge: Yes     | 97.88          | 100      | 1.23  |
| Centrifuge: No      | 99.61          | 100      |       |
| Wavelength 312 nm   | 98.83          | 100      | 0.34  |
| Wavelength 314 nm   | 99.25          | 100      |       |
| Wavelength 316 nm   | 98.58          | 100      |       |
| Amber Glassware     | 100.61         | 100      | 1.68  |
| Colourless Glassware| 98.24          | 100      |       |

Acceptance Limit: % RSD must be ≤ 2.00%

**System suitability study**

The system suitability was evaluated by five replicate analyses of the ranitidine reference standard at a 100% level. The results of system suitability are represented in Table 6. Both % RSD and similarity factors for day 1 and day 2 were found within the acceptance limit.

**Stability of analytical solutions**

Ranitidine reference standard and sample solutions showed good stability in diluent (water) over a period of 72 h when stored at room temperature. Fig. 4 suggested no spectrophotometric degradation during this period. The spectrum of analytical solutions after 72 h was almost similar to the spectrum of freshly prepared solutions.

Table 6: System suitability study for Ranitidine

| Day-1 Determination No. | Absorbance | Similarity Factor | Day-2 Determination No. | Absorbance | Similarity Factor |
|-------------------------|------------|-------------------|-------------------------|------------|-------------------|
| 1                       | 0.34365    |                   | 1                       | 0.34844    |                   |
| 2                       | 0.34397    |                   | 2                       | 0.34916    |                   |
| 3                       | 0.34499    | 0.99              | 3                       | 0.34871    | 1.01              |
| 4                       | 0.34414    |                   | 4                       | 0.34876    |                   |
| 5                       | 0.34368    |                   | 5                       | 0.34791    |                   |
| % RSD: 0.15             |            |                   | % RSD: 0.13             |            |                   |

Acceptance limit: % RSD ≤ 2.00%, Similarity Factor: 0.98-1.02

**Assay of commercial dosage form**

Five different brands of ranitidine tablets were randomly purchased from medicine shop of Dhaka, Bangladesh. Then percentage content of ranitidine was determined by the proposed validated spectrophotometric method. Each experiment was performed in three replicates and are summarized in Table 7.

Table 7: Estimation of Ranitidine in commercial formulations

| Brand | Labeled amount (mg) | Obtained amount (mg) | % Drug content |
|-------|---------------------|----------------------|----------------|
| SP-1  | 150                 | 150.39               | 100.26         |
| SP-2  | 150                 | 148.64               | 99.09          |
| SP-3  | 150                 | 147.36               | 98.24          |
| SP-4  | 150                 | 153.17               | 102.11         |
| SP-5  | 150                 | 151.23               | 100.82         |
CONCLUSION

The experiment propounds a new and simpler pattern of analytical method validation of ranitidine in tablet dosage forms with UV-Visible spectrophotometer. The use of water as a diluent made it cost-effective too. The method is precise and reproducible as well as the percent recovery data was in agreement with the claims in the label. From the concentration ranging from 0.0036 mg/mL to 0.0108 mg/mL, the results were found having linear relationship. It is also found robust, that is, small variations of parameters did not affect the method. It is specific and selective, free of any placebo effect. The analytical solutions also found stable for 72 hours. Further, this propounded method were able to determine the content of ranitidine in five different brands of ranitidine tablets. As the proposed method is easy, rapid, affordable with satisfied accuracy, precision, linearity, specificity, robustness and reproducibility, it can be recommended for the determination of the amount of ranitidine in tablet dosage form.

ACKNOWLEDGEMENT

The first author, Subrata Paul is grateful to Square Pharmaceuticals Limited, Bangladesh for supplying the Ranitidine (sample) and Ranitidine (standard).

Conflict of interest
No conflict of interest to declare.

REFERENCES

1. Ganellin, C. R. Analogue-Based Drug Discovery., 2006, 71-80.
2. Gaginella, T. S.; Bauman, J. H. Drug. Intell. Clin. Pharm., 1983, 17(12), 873-885.
3. Brogden, R.N.; Heel, R.C.; Speight, T. M.; Avery, G. S. Drugs., 1978, 15(2), 93-131.
4. Zeldis, J.B.; Friedman, L.S.; Isselbacher, K.J.; Johnson, D.; Faustino, P.J.; Nguyenpho, A.; Khan, M.A.; Hullahalli, P.R.; Tawakkul, M.A.; Shah, R.B.; Hullahalli, P.R.; Tawakkul, M. A.; Abdel Fattah, L. Anal. Lett., 2002, 36(6), 1055-1073.
5. Beaulieux, N.; Lacroix, P.M.; Sears, R.W.; Wagner, J.A.; Colombo, J.M. Clin. Transl. Sci., 2014.
6. Wagner, J.A.; Colombo, J.M. Clin. Transl. Sci., 2020.
7. Wagner, J.A.; Colombo, J.M. Clin. Transl. Sci., 2020.
8. Shah, R.B.; Allahwali, P.R.; Tawakkul, M.A.; Faustino, P.J.; Nguyenpho, A.; Khan, M.A; Clin. Res. Regul. Aff., 2006, 23(1), 35-51.
9. Haque, A.; Shahrir, M.; Parvin, M.N.; Islam, S.M. Asian J. Pharm., 2011, 1(3), 59-63.
10. Beaulieux, N.; Lacroix, P.M.; Sears, R.W.; Lovering, E.J. Pharm. Sci., 1988, 77(10), 889-892.
11. US Pharmacopeial Convention. United States Pharmacopeia. 26th Edition, Rockville, MD, 2003.
12. Dhanwate, S.S.; Pachauri, A.D.; Ghode, P.D.; Mondal, S.K.; Kabir, A.H.; Hossain, M.A.; Chandran, S.; Singh, R.S. Pharmazie, 2009, 64(1), 22-26.
13. Haque, A.; Shahir, M.; Parvin, M.N.; Islam, S.M; Asian J. Pharm., 2011, 1(3), 59-63.
14. Behera, S.; Ghanta, S.; Ahmad, F.; Santra, S.; Banerjee, S. J. Anal. Bioanal. Techn., 2012, 3(6), 151-17.
15. Vehabovic, M.; Hadzovic, S.; Stambolic, F.; Hadzic, A.; Vranjes, E.; Haracic, E. Int. J. Anal., 2003, 256(1-2), 109-115.
16. Evans, M.B.; Haywood, P.A.; Johnson, D.; Martin-Smith, M.; Munro, G.; Wahlich, J.J. Pharm. Biom., 1998, 7(1), 1-22.
17. Wong, C.F.; Peh, K.K.; Yuen, K.H. Chromatogr. B Biomed. Appl., 1998, 71(1), 205-210.
18. Kelani, K.M.; Aziz, A.M.; Hegazy, M.A.; Abdel Fattah, L. Anal. Lett., 2002, 35(6), 1055-1073.
19. Desta, K.; Amare, M. Chem. Int., 2017, 3(3), 288-295.
20. ICH Guideline; Validation of Analytical Procedures: Text and Methodology. Topic Q 2 R1, (2005). Geneva, Switzerland.
21. United States Pharmacopeia United States Pharmacopeial Convention, 26th Edition, Rockville, MD, 2003.
22. Haque, A.; Naznin, A.; Kabir, A.H.; Hossain, M.K.; Islam, S.A. Dhaka Univ. J. Pharm., 2019, 11(8), 2886-2890.
23. Chandran, S.; Singh, R.S. Pharmazie, 2007, 62(1), 4-14.
24. Naseef, H.; Moqadi, R.; Qurt, M. J. Anal. Methods Chem., 2018, 190, 2510.
25. Batrawi, N.; Naseef, H.; Al-Rimawi, F. J. Anal. Methods Chem., 2017, 15,29280.
26. Sharma, S.; Goyal, S.; Chauhan, K. Int. J. App. Pharm., 2018, 10(6), 8-15.
27. Fda. Guidance for Industry: Validation of Analytical Procedures: Definition and terminology., 2010.
28. Miller, J.N. Analyst., 1991, 116(1), 3-14.